- Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiii
- Warming temperatures and changing consumer habits have increased parasite pressure and spread across geographies, bringing with them increased public health risk.
- Experts recommend monthly treatment for zoonotic parasitesiv, like Echinococcus granulosus, a type of tapeworm.
- Credelio Quattro launch expected in first quarter of 2025
GREENFIELD, Ind., Oct. 7, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), becoming the broadest approved canine oral parasiticide with its protection against six types of parasites—fleas, ticks, heartworms, and the three risky intestinal parasites—roundworms, hookwormsii and tapeworms. Credelio Quattro is a single, monthly chewable tablet for dogs eight weeks of age or older.
